Institut Gustave-Roussy

Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility (2018) Machiela MJ, Gruenewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, et al. Conference contribution Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma (2018) Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, et al. Journal article Multiple new susceptibility loci identified in genome-wide association study of Ewing sarcoma (2018) Machiela MJ, Gruenewald TG, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, et al. Conference contribution A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2018) Ahrens M, Scheich S, Goekbuget N, Boleti E, Gruenwald V, Escudier B, Goebell P, et al. Conference contribution Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility (2018) Machiela MJ, Grunewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, et al. Journal article SUNNIFORECAST - A phase II study of Nivolumab in combination with Ipilimumab versus Standard of care in advanced or metastatic non-clear cell renal cell carcinoma (2018) Scheich S, Ahrens M, Goekbuget N, Boleti E, Burkholder , Escudier BJ, Goebell P, et al. Conference contribution Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017) Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al. Journal article The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report (2016) Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovee JVMG, et al. Journal article Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, et al. Journal article Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project+ (2015) Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, et al. Journal article